With increasing popularity of Industry Theaters, ATS 2015 will deliver more offerings than ever before. Professionals will lead a total of 19 Industry Theater and Mini Industry Theater discussions in the Exhibit Hall. Have lunch while learning about new product launches and treatment options. Complimentary boxed lunch provided by the ATS while supplies last.
Sunday, May 17
11:45 a.m. to 12:30 p.m.
Industry Theater 1
Exploring Risk Reduction in Thrombosis
This lecture will discuss treatment options for patients with deep vein thrombosis and pulmonary embolism, and how they can reduce the risk of recurrent thrombotic events. This promotional educational activity is not accredited. The program content is developed by Janssen Pharmaceuticals, Inc. Speakers are present on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines. In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company sponsored programs.
Speaker: Joseph K. Choo, MD, FACC, Interventional Cardiologist, Ohio Heart and Vascular Center, Inc, Cincinnati, OH
Company: Janssen Pharmaceuticals, Inc.
1 to 1:45 p.m.
Industry Theater 1
Personalized Medicine: Dealing with Breathlessness, Dealing with Risk
(Open to non-U.S. attendees only)
GSK is committed to the discovery and development of innovative respiratory solutions and furthering disease understanding to enable people with asthma and COPD to do more, feel better, and live longer. We believe that the opportunity for scientific discussion provided by congresses plays an important role in realizing this commitment.
Speakers: Chair: Neil Barnes Medical Head, Global Respiratory Franchise, GSK; Dave Singh, Dealing with Breathlessness, Professor of Clinical Pharmacology and Respiratory Medicine, University of Manchester, University Hospital Of South Manchester NHS Foundation Trust, Manchester, UK; Ian Pavord Dealing with Risk, A Role for Biomarkers? Professor of Respiratory Medicine, University of Oxford, Oxford, UK
Company: GlaxoSmithKline
11:45 a.m. to 12:30 p.m.
Industry Theater 2
Factors to Consider in the Diagnosis and Management of Allergic Asthma: A Modular Speaker Program
Allergic asthma is a heterogeneous disease. You are cordially invited to join us for an engaging and actionable discussion about the heterogeneity and complexity of allergic asthma, as well as the clinical assessment of its control.
Speaker: Kevin Murphy, MD, Boys Town National Research Hospital, Boys Town, NE
Company: Genentech, Inc.
1 to 1:45 p.m.
Industry Theater 2
Do You Have a Patient with Shortness of Breath Due to a Chronic PE? Have You Considered CTEPH
Chronic thromboembolic pulmonary hypertension (CTEPH) is the only potentially curable (via pulmonary thromboendarterectomy, PTE) form of pulmonary hypertension (PH). Because it is potentially curable, it’s vitally important that CTEPH not be mistaken for other forms of PH or for a “chronic” pulmonary embolism (PE) or “unresolved clot.” Attendees will better understand CTEPH and its relation to acute PE, and they will appreciate the importance of reasonable suspicion, accurate diagnosis, and timely referral to an experienced center.
Speakers: Gustavo Heresi-Davila, MD, Assistant Professor of Medicine, Medical Director, Pulmonary Thromboendarterectomy Program, Department of Pulmonary and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH, CTEPH.com Editorial Board Member; Michael Madani, MD, Professor and Chief, Cardiovascular & Thoracic Surgery, Director, Sulpizio Cardiovascular Center-Surgery, Surgical Director, UCSD PTE Program, University of California San Diego Medical Center, San Diego, CA, CTEPH.com Editorial Board Member
Company: Bayer HealthCare Pharmaceuticals
11:30 a.m. to Noon
Mini Industry Theater
The Evolving Role of Parenteral Therapy in PAH
Join us for a live presentation about the evolving role of parenteral therapy in light of guideline and therapy updates, as well as discussion of a communication technique to help optimize the parenteral therapy conversation and increase patient understanding.
Company: United Therapeutics Corporation
12:30 to 1 p.m.
Mini Industry Theater
IPF Expert Perspective: Clinical Features, Progression, and Monitoring of Disease
IPF (Idiopathic Pulmonary Fibrosis) remains a challenging disease to diagnose and manage. Please join an IPF expert for an engaging dialogue about clinical manifestations, the unpredictable course, and monitoring of IPF. The program will focus on topics highly relevant to physicians and other health care professionals treating IPF patients.
Company: Genentech, Inc.
1:30 to 2 p.m.
Mini Industry Theater
A Voyage Through the Lungs: Cytokines, Effector Cells, and Clinical Biomarkers in Asthma
Join us for an interactive exploration of the pathophysiology of moderate to severe asthma. Discover the origins of hallmark signs such as airway hyperreactivity and mucus overproduction; explore the role of important Th2 cytokines such as IL-13, IL-4 and IL-5; and learn how biomarkers can reflect the activity of those cytokines.
Company: Genentech, Inc.
Monday, May 18
11:45 a.m. to 12:30 p.m.
Industry Theater 1
The Role of Bronchodilators in the Long-Term Maintenance Treatment of Patients with COPD: A Review of the Data
Discover the mist. A dynamic presentation of the role of bronchodilators in the long-term maintenance treatment of patients with COPD. An expert speaker will review the efficacy and safety data of bronchodilator maintenance treatments as well as the features of the inhaler.
Company: Boehringer Ingelheim Pharmaceuticals, Inc.
1 to 1:45 p.m.
Industry Theater 1
Are We Gaining the Maximum Benefit from Bronchodilators in COPD?
(Open to non-U.S. based physicians only)
During this industry theater supported by Novartis, Chairman Ken Chapman will pose pertinent clinical questions on COPD therapies to a faculty of world-renowned experts. The program will highlight the fundamental role of bronchodilators in COPD management, and will discuss key data on indacaterol and glycopyrronium, as well as the efficacy and safety profile of the dual bronchodilation combination indacaterol/glycopyrronium. Inhaled corticosteroids (ICS) have been used in COPD management for many years but their use in practice is often contrary to guideline recommendations. New and recent evidence— demonstrating that, for many patients, effective bronchodilation may be a better option than ICS-containing regimens—will be shown. The appropriate ICS patient, data from recent ICS withdrawal trials, and use of alternative agents will be discussed.
Speakers: Chair: Professor Ken Chapman, University of Toronto, Canada; Effective Use of Bronchodilators in COPD; Professor José Jardim, Federal University of Sí£o Paulo, Brazil; Re-thinking the Use of ICS in COPD; Professor Marc Miravitlles, Hospital Universitari Vall d’Hebron, Barcelona, Spain
Company: Novartis Pharma AG
11:45 a.m. to 12:30 p.m.
Industry Theater 2
Want to Add More to Your PAH Treatment Strategy?
Join a panel of experts for a poster-themed discussion on disease progression in pulmonary arterial hypertension, adding prostacyclin class therapy in appropriate patients, and how an inhaled prostacyclin-class therapy may help. Topics include diagnosis, clinical trial study design, efficacy, side effects, dosing, and therapy management. Lunch provided.
Speakers: Steven Nathan, MD, FCCP, Medical Director, Advanced Lung Disease and Lung Transplant Programs, Inova Fairfax Hospital, Falls Church, VA; Lynette Brown, MD, PhD, Associate Director, Pulmonary Hypertension Program, Intermountain Medical Center, Murray, UT; Glenna Traiger, RN, MSN, CNS-BC, Pulmonary Hypertension CNS, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Company: United Therapeutics Corporation
1 to 1:45 p.m.
Industry Theater 2
The Role of Nitric Oxide (NO) in the Pathology of PAH (WHO Group 1) and CTEPH (WHO Group 4)
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are two different forms of pulmonary hypertension, characterized by elevated pulmonary artery pressures and increased pulmonary vascular resistance. Impaired synthesis of endogenous nitric oxide contributes to the pathology of both diseases. PH experts will present and discuss a CTEPH case and a PAH case that are typical of patients who may be encountered in practice.
Speakers: Nicholas S. Hill, MD, Professor of Medicine and Chief of Pulmonary, Critical Care, and Sleep Division, Tufts University School of Medicine, Boston, MA; Nick H. Kim, MD, Clinical Professor of Medicine and Director of Pulmonary Vascular Medicine, University of California School of Medicine, San Diego, CA
Company: Bayer HealthCare Pharmaceuticals
11:30 a.m. to Noon
Mini Industry Theater
Pattern Recognition and Identification of Idiopathic Pulmonary Fibrosis (IPF)
Come explore a hands-on learning adventure, presented by thought-leader experts on IPF. This program features a uniquely designed, high-impact visual exploration of IPF. Participants will also be invited to test their new knowledge via polling questions interspersed throughout the program.
Company: Genentech, Inc.
12:30 to 1 p.m.
Mini Industry Theater
Pattern Recognition and Identification of Idiopathic Pulmonary Fibrosis (IPF)
Come explore a hands-on learning adventure, presented by thought-leader experts on IPF. This program features a uniquely designed, high-impact visual exploration of IPF. Participants will also be invited to test their new knowledge via polling questions interspersed throughout the program.
Company: Genentech, Inc.
1:30 to 2 p.m.
Mini Industry Theater
Pattern Recognition and Identification of Idiopathic Pulmonary Fibrosis (IPF)
Come explore a hands-on learning adventure, presented by thought-leader experts on IPF. This program features a uniquely designed, high-impact visual exploration of IPF. Participants will also be invited to test their new knowledge via polling questions interspersed throughout the program.
Company: Genentech, Inc.
Tuesday, May 19
11:45 a.m. to 12:30 p.m.
Industry Theater 1
An Alternative Mode of Prostacyclin Delivery for the Treatment of PAH
Prostacyclin class therapy has been recommended for treatment of PAH for more than a decade. This session will provide a forum to discuss clinical and practical insights of an alternative delivery of a prostacyclin analogue.
Company: United Therapeutics Corporation
11:45 a.m. to 12:30 p.m.
Industry Theater 2
New Insights into the Management of COPD
This industry theater will focus on the importance of optimal bronchodilation in treating patients with COPD. Key points of emphasis will include residual symptoms despite treatment, the central role of bronchodilation in treating COPD, the potential additive effects of using a long-acting muscarinic antagonist (LAMA) and a long-acting beta agonist (LABA), and the appropriate use of inhaled corticosteroids.
Speakers: Bartolome R. Celli, MD, Professor of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, and Donald A. Mahler, MD, Emeritus Professor of Medicine, Geisel School of Medicine at Dartmouth, Director, Pulmonary Function Laboratory, Dartmouth-Hitchcock Medical Center
Company: Novartis Pharmaceuticals
11:30 a.m. to Noon
Mini Industry Theater
Treatment of the Respiratory Manifestations of Symptomatic Sarcoidosis
This program will address the unmet need in the treatment of respiratory manifestations of sarcoidosis and introduce an FDA-approved treatment option.
Speaker: Robert P. Baughman, MD, University of Cincinnati Medical Center
Company: Mallinckrodt Pharmaceuticals
12:30 to 1 p.m.
Mini Industry Theater
Treatment of the Respiratory Manifestations of Symptomatic Sarcoidosis
This program will address the unmet need in the treatment of respiratory manifestations of sarcoidosis and introduce an FDA-approved treatment option.
Speaker: Daniel Culver, DO, Cleveland Clinic
Company: Mallinckrodt Pharmaceuticals
1:30 to 2 p.m.
Mini Industry Theater
When Struggling with COPD Symptoms: Assess Your Treatment Plan
The objective of this presentation is to provide pertinent, balanced information to healthcare professionals on the efficacy and safety of nebulized long-acting bronchodilator therapy for patients with COPD. It is designed to afford healthcare professionals the opportunity to review, evaluate and discuss the role of nebulized long-acting bronchodilator therapy as an option for patients with COPD, including chronic bronchitis and emphysema, in order to make informed treatment decisions for their patients.
Speaker: Sanjay Sethi, MD, FACP, Professor, Department of Medicine, Chief, Division of Pulmonary, Critical Care, and Sleep Medicine, University at Buffalo, State University of New York, Buffalo, NY
Company: Sunovion Pharmaceuticals, Inc.